Overexpression of MIR9 indicates poor prognosis in acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 78-86

  Sugita, Fusako ^a   Maki, Kazuhiro ^a   Nakamura, Yuka ^a   Sasaki, Ko ^a   Mitani, Kinuko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute lymphoblastic leukemia; MicroRNA; MIR9; Overall survival; Prognostic factor; Relapse free survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMATINIB; MICRORNA 9; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; YOUNG ADULT;

EID: 84891349993     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.790023     Document Type: Article

References (43)

1. Pidala J, Djulbegovic B, Anasetti C, et al. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev 2011; (10): CD008818.
2. Graux C. B iology of acute lymphoblastic leukemia (ALL): Clinical and therapeutic relevance. Transfus Apher Sci 2011; 44: 183-189.
3. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
4. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
5. Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci 2010; 101: 2309-2315.
6. Bhagavathi S, Czader M. MicroRNAs in benign and malignant hematopoiesis. Arch Pathol Lab Med 2010; 134: 1276-1281.
7. Havelange V., Garzon R. MicroRNAs: Emerging key regulators of hematopoiesis. Am J Hematol 2010; 85: 935-942.
8. Ye H, Liu X, Lv M, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res 2012; 40: 5201-5214.
9. Lv M, Zhang X, Jia H, et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-Alpha and cAMP/PKA pathways. Leukemia 2012; 26: 769-777.
10. Fabbri M, Croce C M. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 2011; 18: 266-272.
11. Ghisi M, Corradin A, Basso K, et al. Modulation of microRNA expression in human T-cell development: Targeting of NOTCH3 by miR-150. Blood 2011; 117: 7053-7062.
12. L iX, Sanda T, Look AT, et al. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med 2011; 208: 663-675.
13. Schotte D, de Menezes RX, Akbari Moqadam F, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011; 96: 703-711.
14. Zhang H, Luo XQ, Zhang P, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One 2009; 4: E7826.
15. Maki K, Yamagata T, Sugita F, et al. A berrant expression of MIR9 indicates poor prognosis in acute myeloid leukaemia. Br J Haematol 2012; 158: 283-285.
16. Kantarjian HM, O ' B rien S, Smith TL, et al. Results of treatment with hyper-CVAD, adose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
17. Thomas DA, Cortes J, O ' Brien S, et al. Hyper-CVAD program in Burkitt ' s-Type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461-2470.
18. De Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413.
19. Barnett MJ, Greaves MF, Amess JA, et al. Treatment of acute lymphoblastic leukaemia in adults. Br J Haematol 1986; 64: 455-468.
20. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 1987; 14: 73-77.
21. Ferra C, Berlanga JJ, Gallardo D, et al. Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. Leuk Lymphoma 2000; 39: 583-590.
22. Wouters BJ, Jorda MA, Keeshan K, et al. Distinct gene expression profi les of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-3714.
23. Hildebrandt MA, Gu J, Lin J, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728.
24. Ma L, Young J, Prabhala H, et al. miR-9, aMYC/MYCN-Activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
25. Schraivogel D, Weinmann L, Beier D, et al. CAMTA1 is a novel tumour suppressor regulated by miR-9/9 in glioblastoma stem cells. EMBO J 2011; 30: 4309-4322.
26. Selcuklu SD, Donoghue MT, Rehmet K, et al. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profi ling in breast cancer cells. J Biol Chem 2012; 287: 29516-29528.
27. Rodriguez-Otero P, Roman-Gomez J, Vilas-Zornoza A, et al. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family. Br J Haematol 2011; 155: 73-83.
28. Hancock RL. Th eoretical mechanisms for synthesis of carcinogeninduced embryonic proteins: XVIII. Biomethylation and differentiation. Med Hypotheses 1987; 24: 95-102.
29. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol 2010; 12: 209-211.
30. Laneve P, Gioia U, Andriotto A, et al. A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res 2010; 38: 6895-6905.
31. Klapproth K, Wirth T. Advances in the understanding of MYCinduced lymphomagenesis. Br J Haematol 2010; 149: 484-497.
32. Wen AY, Sakamoto KM, Miller L S. The role of the transcription factor CREB in immune function. J Immunol 2010; 185: 6413-6419.
33. Lin J, Lwin T, Zhao JJ, et al. Follicular dendritic cell-induced micro RNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin' s B-cell lymphomas. Leukemia 2011; 25: 145-152.
34. Nie K, Gomez M, Landgraf P, et al. MicroRNA-mediated downregulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: A potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol 2008; 173: 242-252.
35. Onnis A, De Falco G, Antonicelli G, et al. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 2010; 5: E12960.
36. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10: 299-304.
37. Gunji H, Waga K, Nakamura F, et al. TEL/AML1 shows dominantnegative effects over TEL as well as AML1. Biochem Biophys Res Commun 2004; 322: 623-630.
38. Asnafi V Buzyn A, Le Noir S, et al. NOTCH1/FBXW& mutation identifi es a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): A Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009; 113: 3918-3924.
39. Mansour MR, Sulis ML, Duke V, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27: 4352-4356.
40. Baldus CD, Th ibaut J, Goekbuget N, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009; 94: 1383-1390.
41. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69: 4443-4453.
42. Han BW, Feng DD, L i Z G,et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 2011; 20: 4903-4915.
43. D e Oliveira JC, Brassesco MS, Scrideli CA, et al. MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2012; 59: 599-604.